


<section-header><section-header><section-header><section-header><section-header><section-header><section-header><text><text><text>

Disclosures


- Salary awards
 - BC Children's Hospital Foundation
 - Michael Smith Foundation for Health Research
 - Canadian Child Health Clinician Scientist Program
- Research/Project Funding
 - Merck, VBI Vaccines, GlaxoSmithKline, Pfizer, Sanofi-Pasteur, Seqirus, Symvivo
- All funds have been paid to my institute
- Not received any personal payments







In Canada				
 Agreements annou 	inced with	I		
Company	Vaccine type	Clinical phase	# doses (Canada)	Reported efficacy (vs. symptomatic disease)
Pfizer/BioNTech	RNA	Phase 3	≥20m doses	95% (2 doses)
Moderna	RNA	Phase 3	≤56m doses	95% (2 doses) 92% (1 dose)
Oxford University/Astra Zeneca	Viral vector	Phase 3	≤20m doses	70% (2 doses)
Johnson & Johnson	Viral vector	Phase 3	≤38m doses	66% (1 dose) – press release moderate to severe disease
Novavax	Subunit	Phase 3	≤76m doses	89% (2 doses) – press release
Medicago	Subunit	Phase 3	≤76m doses	Trials ongoing
Sanofi/GlaxoSmithKline	Subunit	Phase 2	≤72m doses	Development paused



Outstanding questions = we don't know the answers

- Mechanism of protection
- Duration of protection, including 1 vs. 2 doses
- Effectiveness against new variant strains
- Safety, immunogenicity and effectiveness in populations outside trials
 - Extremes of age
 - Multiple/severe comorbidities
 - Immunocompromised
 - Pregnancy and breast feeding

